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Background: Lower airway biomarkers of restored cystic ﬁbrosis transmembrane conductance regulator (CFTR) function are limited. We
hypothesized that fractional excretion of nitric oxide (FENO), typically low in CF patients, would demonstrate reproducibility during CFTR-
independent therapies, and increase during CFTR-speciﬁc intervention (ivacaftor) in patients with CFTR gating mutations.
Methods: Repeated FENO and spirometry measurements in children with CF (Cohort 1; n = 29) were performed during hospital admission for
acute pulmonary exacerbations and routine outpatient care. FENO measurements before and after one month of ivacaftor treatment (150 mg every
12 h) were completed in CF patients with CFTR gating mutations (Cohort 2; n = 5).
Results: Cohort 1: Mean forced expiratory volume in 1 s (FEV1 % predicted) at enrollment was 72.3% (range 25%–102%). Mean FENO measurements
varied minimally over the two inpatient and two outpatient measurements (9.8–10.9 ppb). There were no clear changes related to treatment of pulmonary
exacerbations, gender, genotype or microbiology, and weak correlation with inhaled corticosteroid use (P b 0.05). Between the two inpatient
measurements, FEV1% predicted increased by 7.3% (P b 0.03) and FENO did not change. In Cohort 2, mean FENO increased from 6.6 ppb (SD = 2.19)
to 11.8 ppb (SD = 4.97) during ivacaftor treatment. Mean sweat chloride dropped by 58 mM and mean FEV1 % predicted increased by 10.2%.
Conclusions: Repeated FENOmeasurements were stable in CF patients, whereas FENO increased in all patients with CFTR gatingmutations treated with
ivacaftor. Acute changes in FENO may serve as a biomarker of restored CFTR function in the CF lower airway during CFTR modulator treatment.
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: CFTR biomarker; FENO; Nitric oxide; Cystic ﬁbrosis; CFTR modulatorAbbreviations: ATS, American Thoracic Society; BMI, body mass index; CF,
cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CI,
confidence interval; COPD, chronic obstructive pulmonary disease; FENO,
fractional excretion of nitric oxide; FEV1, forced expiratory volume in 1 s; ICS,
inhaled corticosteroids; IQR, interquartile range; NO, nitric oxide; PCD, primary
ciliary dyskinesia; SD, standard deviation.
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Cystic fibrosis (CF) is caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene, which
encodes a cAMP-regulated chloride and bicarbonate channel
[1–6]. Recent studies indicate that the CFTR modulator
ivacaftor potentiates CFTR and improves the gating of several
disease-causing mutations [7,8]. Ivacaftor has been studied in
children and adults with the G551D CFTR mutation, leading to
unprecedented improvements in lung function, weight, and
patient symptoms, as well as reductions in sweat chloride
[9–11]. The use of ivacaftor in patients with the G551D CFTRCystic Fibrosis Society. This is an open access article under the CC BY-NC-ND
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gained regulatory approval. Ivacaftor is also being examined as
a co-therapy targeting F508del CFTR, the most common cause
of CF. Despite these exciting recent results, there currently are
no specific biomarkers to detect restored CFTR function in the
lower airways, and available biomarkers of CFTR do not
correlate with improvement in lung function. The need to
identify pulmonary biomarkers that reflect CFTR activity and
are easily monitored in clinical trials has recently been
highlighted by independent investigators and the FDA [12–14].
Nitric oxide (NO) is an important signaling molecule
produced by airway cells (and other cell types) that is related
to numerous airway processes including ciliary activity, ion
transport, host defense, inflammation, and vascular tone [15].
Fractional excretion of nitric oxide (FENO) is reduced in CF
patients with normal or reduced lung function compared to
non-CF control subjects, and it recently has been demonstrated
that FENO has an inverse correlation with the lung-clearance
index [16,17]. Measurements of FENO are routinely used to
monitor disease status in asthma, which is thought to be linked
to eosinophilic inflammation in the context of this patient
population [18]. It is unclear exactly why FENO is reduced in
CF, but hypotheses include trapping of locally produced NO in
the thick mucus blanket characteristic of the CF airway,
decreased production by deficient NO synthase, increased NOA
Fig. 1. CONSORT flowchart diagram relevantconsumption, or defects in ciliary function [15]. All of these
hypotheses are directly or indirectly related to described CFTR
functions. Exhaled NO is extremely low in patients with
primary ciliary dyskinesia (PCD), and nasal-exhaled NO is a
recently validated biomarker of ciliary activity for the diagnosis
of PCD [19–22]. Thus, FENO measurements may serve as a
marker of mucociliary clearance (and other pulmonary deficits)
in the context of CF. Due to the reduction of FENO in the CF
airway and its ease of measurement, standardized equipment
and procedures, and the direct relationship of FENO to ciliary
dysfunction in PCD, we hypothesized that changes in FENO
could potentially serve as a novel biomarker reflecting restored
CFTR activity in the lower airways of CF patients.
In the current study, we examined FENO in a group of
patients admitted for treatment of pulmonary exacerbations
(Cohort 1) and in a second pilot group of CF patients with
gating mutations who were candidates for ivacaftor therapy
(Cohort 2). We examined FENO reproducibility in Cohort 1
over the course of inpatient treatment of pulmonary exacerba-
tions and during outpatient follow-up, including intrasubject
and intersubject variabilities, correlations with lung function
(FEV1 % predicted), and relationships to genotype, microbiol-
ogy, and concomitant therapies. In Cohort 2, we examined
FENO, FEV1, sweat chloride, weight, and body mass index
(BMI) before and after 4 weeks of ivacaftor treatment (150 mgB
to this study. (A) Cohort 1; (B) Cohort 2.
Table 1
Cohort 1 demographic information (n = 34 subjects).
Parameter Value a
Age (mean, range) 15.2 yr (5.0–21.2)
Gender (male:female) 13:21
Mean admission FEV1
b (range) 72.3 (25.0–102.0)
Pseudomonas aeruginosa (n) 25
Methicillin-sensitive Staphylococcus aureus (n) 22
Methicillin-resistant Staphylococcus aureus (n) 20
Stenotrophomonas maltophilia (n) 15
Hemophilus influenza (n) 18
Achromobacter xyloxidans (n) 2
Nontuberculous mycobacterium (n) 1
Any fungus (n) 21
Concomitant pulmonary medications (chronic)
rhDNAse alpha (n) 31
Hypertonic saline (n) 31
Azithromycin (n) 25
Inhaled corticosteroid (n) 12 c
FEV1, forced expiratory volume in 1 s.
Bacterial names are italicized.
a Expressed as mean (range) or frequency.
b Four subjects did not have PFT data within 72 h of admission or at follow-
up visits (within 6 months). One of these subjects was receiving treatment with
ICS.
c One subject was not included in the analysis (see b).
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FENO may be specific for restored CFTR function in CF
patients in the context of CFTR modulator treatment.
2. Methods
2.1. Institutional review board approval
This study was approved by the Institutional Review Board
of Cincinnati Children's Hospital Medical Center, protocol #
2011–2125. All patients signed informed consent or assent
(with parental consent for patients b12 years of age) prior to any
study-related measurements.
2.2. Subjects
Patients in Cohort 1 (Fig. 1A) were enrolled within 72 h of
admission to the hospital for a pulmonary exacerbation (as
defined by their treating physician). Inclusion criteria were age
N6 years, diagnosis of CF based on CF Foundation guidelines,
and ability to provide informed consent (or assent). Exclusion
criteria included age b6 years or secondary diagnoses that in
the opinion of the investigator might put patients at risk by
study participation or limit their ability to complete the study.
FENO was measured according to American Thoracic Society
(ATS) guidelines [23] using the NIOX Mino system (Aerocrine
Inc. USA, Morrisville, NC, USA) and reported as ppb, and
spirometry was measured using ATS guidelines [24]. Mea-
surements were performed four times, including within 72 h of
admission, near the time of discharge (typically 10–14 days of
inpatient treatment), and twice during routine follow-up for
clinical care (at approximately 1 month and 2–4 months
after discharge). Clinical data collected throughout the study
included age, height, weight, BMI, gender, genotype, micro-
biology, airway clearance, and other medications. Two patients
in Cohort 1 (both with G551D/F508del CFTR genotypes) were
prescribed ivacaftor therapy prior to and throughout the four
measurements.
Patients enrolled in Cohort 2 (Fig. 1B) included five CF
patients with rare CFTR gating mutations (S549N/S549N in
three subjects, G178R/F508del in one subject, and S549R/
F508del in one subject) who were candidates for ivacaftor
therapy. The same inclusion and exclusion criteria were used as
in Cohort 1, except that patients were enrolled during routine
outpatient encounters. The patients underwent the same
measurements as described for Cohort 1 on two occasions;
once prior to prescription of ivacaftor therapy and a second
after completing 1 month of therapy (28–30 days). No subjects
in Cohort 2 had pulmonary exacerbations or changes in therapy
beyond the addition of ivacaftor during the study. Sweat
chloride was stimulated by pilocarpine iontophoresis [9,25].
Sweat was collected with standard gauze pads in three subjects
and the Wescor Macroduct 3700 system in two subjects
(Wescor, Inc., Logan, Utah and EliTech group). Sweat-chloride
concentration was determined by a chloridometer (Labconco
Digital Chloridometer, Labconco Corporation, Kansas City,
Missouri). One subject (CF05) had a baseline sweat-chloridevalue that was of insufficient quantity for chloride measure-
ment. For this subject, the baseline sweat chloride value was
obtained from the medical record (part of CF diagnosis,
performed within 12 months of the initiation of ivacaftor).2.3. Statistical analysis
In the analyses for Cohort 1, linear mixed-effects models were
used to assess longitudinal changes in both FEV1 % predicted and
FENO. Exploratory analyses revealed that heterogeneity in
observed FENO related to whether the measurement was obtained
at inpatient or outpatient periods. We therefore included separate
variance components for inpatient and outpatient measurements.
Estimates of intersubject and intrasubject variabilities were
obtained via restricted maximum likelihood or REML and are
expressed as standard deviation [SD; 95% confidence interval
(CI)]. Temporal associations between FENO and FEV1 %
predicted were examined by including FEV1 % predicted as a
covariate and the interaction of FEV1 % predicted with visit in the
aforementioned model. Influence diagnostics and residual plots
were examined for each linear mixed-effects model. A simulated
adjustment was applied to all P values arising from between-visit
comparisons.
Given the smaller sample size in Cohort 2, descriptive
statistics and bivariate associations for pre- and post-treatment
assessments were performed. Results for differences between
visits are expressed as the estimated mean difference (95%
t-interval). Effect sizes are reported for outcomes of interest
described by Cohen's d [26] using the between-group t-test
value as a conservative measure of ivacaftor effect [27].
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A total of 34 patients were enrolled in Cohort 1 at the time of
admission for pulmonary exacerbations; 30 received pulmonary-
function testing within 72 h of admission (baseline) and 29 had
four measurements completed over the time course of the study
(two during inpatient treatment, two during outpatient clinic
follow-up). One subject failed to return for outpatient visits
over the 6 months following inpatient treatment, and this
subject's data was not included in the final dataset. Table 1
summarizes demographic information for Cohort 1 subjects.
Patients typically were children and adolescents admitted for
treatment of uncomplicated pulmonary exacerbations, and all
patients were pancreatic insufficient with CFTR mutations
predicted to have minimal (if any) CFTR function. The vast
majority of Cohort 1 subjects received chronic treatment with
rhDNAse, hypertonic saline, and azithromycin, and 11 had
concomitant use of inhaled corticosteroids (ICS). Sputum
pathogens were as expected for a cohort of CF children and
adolescents admitted for treatment of acute pulmonary
exacerbations.
Summary data regarding lung function (FEV1 % predicted)
and FENO (ppb) across the two inpatient and two out-
patient visits are shown in Table 2. The visit number of each
measurement also is included. The two inpatient measurements
were conducted approximately a median (interquartile range)
of 7.0 (5.5–10.5) days apart, while the first and second
outpatient measurements (Visits 3 and 4) were performed a
median of 40 (20–70) and 98 (72–132) days after the
hospital admission, respectively. As expected from longitudi-
nal analyses, mean ± SD change in FEV1 % predicted
improved over the two inpatient measurements, increasing by
approximately 7.30% ± 9.91 over the course of therapy (P =
0.03). The FEV1 % predicted values measured at the two
outpatient visits were intermediate to the admission and
discharge values, and the difference in FEV1 % predicted
between the two outpatient visits was not statistically
significant (P = 0.60). The mean FENO levels at the first and
second measurements were within 1 ppb and did not
demonstrate significant change over the period of exacerbation
treatment. The mean FENO levels at the third and fourth
measurements (outpatient) differed by b0.5 ppm and wereTable 2
Cohort 1 changes in FENO and FEV1 over the four study visits.
a
Parameter Inpatient treatment for
acute pulmonary
exacerbation
Outpatient clinic visits
Visit number Visit 1 Visit 2 Visit 3 Visit 4
FENO (ppb) 10.5 (10.1) 9.8 (8.3) 10.9 (6.9) 10.8 (5.6)
FEV1 (% predicted) 72.3 (18.7) 79.2 (16.4)
b 77.6 (22.3) 76.9 (18.8)
FENO, fractional excretion of exhaled nitric oxide; FEV1, forced expiratory
volume in 1 s.
a Results are expressed as mean (standard deviation).
b P b 0.05 compared with Visit 1.similar to the inpatient values. Influence of individual
observations was measured according to Cook's distance and
did not indicate undue influence on regression estimates
potentially caused by the two subjects with reported ivacaftor
use.
The intrasubject variability of FENO measurements during
inpatient treatment of pulmonary exacerbations was 2.35 ppm
(95% CI: 1.87 to 3.18) and the intersubject variability was
8.93 ppm (95% CI: 7.06 to 12.14). Similar to the repeated
inpatient measurements, the intrasubject variability of FENO
measurements during outpatient visits (which were much
further apart in time) was lower (3.71 ppm, 95% CI: 2.97 to
4.96) compared with the intersubject variability that was
5.04 ppm (95% CI: 3.82 to 7.43). The ratio of estimated
intersubject and intrasubject variance components indicated
that 81.6% of the FENO variability was due to intersubject
variability.
We examined whether relationships were present between
FENO and FEV1 % predicted in Cohort 1 over the course of
the study. The association between FENO and FEV1 %
predicted was not statistically significant, overall or by visit.
Linear mixed-effects models indicated that there were no
significant associations between FENO and gender, genotype,
or microbiology [presence of Pseudomonas aeruginosa,
methicillin-sensitive or methicillin-resistant Staphylococcus
aureus, any fungus, and Stenotrophomonas maltophilia], or
concomitant use of rhDNAse, hypertonic saline, or azithromycin.
Due to the known relationship between FENO and asthma, we
examined FENO and FEV1 % predicted associations in CF
subjects by including reported ICS prescription (a surrogate
for asthma comorbidity, n = 11) and its interaction with FEV1
% predicted as covariates in the mixed-effects model for
FENO. The association between FENO and FEV1 % predicted
tended to be higher in those CF patients prescribed ICS
over the four visits compared with those not on ICS
(difference ± standard error of regression coefficients for the
two groups: 0.14 ± 0.07, P = 0.04).
Five patients with rare CFTR gating mutations who were
candidates for ivacaftor therapy (Cohort 2) were evaluated by
their treating physician for initiation of treatment. Table 3
summarizes the demographic information of these subjects.
Patients were adolescents to young adults (range of ages 11–
20 years), all of which were pancreatic insufficient with second
CFTR mutations predicted to have minimal function (see
Methods). All Cohort 2 subjects received chronic treatment
with rhDNAse, hypertonic saline, and azithromycin (Table 3).
Four patients grew Pseudomonas at the time of starting
ivacaftor and three also grew methicillin-sensitive S. aureus.
Table 4 summarizes changes in FENO, FEV1 % predicted,
sweat chloride, and weight over 4 weeks of ivacaftor treatment.
Importantly, the mean FENO value nearly doubled over the
period of treatment relative to baseline (difference: 5.20 ppm,
95% CI: 1.54 to 8.86), which was associated with increases in
FEV1 % predicted and reductions in sweat chloride. The
individual baseline and post-treatment values for FENO, FEV1
% predicted, sweat chloride, and weight for Cohort 2 are shown
for each subject in Fig. 2A–D.
Table 3
Cohort 2 demographic information (n = 5 subjects).
Parameter Value a
Age (mean, range) 13.6 yr (11–20)
Gender (male:female) 2:3
Mean baseline FEV1 (SD) 95.2 (12.1)
Pseudomonas aeruginosa (n) 4 b
Staphylococcus aureus (n) 5
Concomitant chronic medications
rhDNAse alpha (n) 5
Hypertonic saline (n) 5
Azithromycin (n) 5
Pancreatic enzymes (n) 5
Inhaled antibiotic 3 c
ICS (n) 1
Albuterol (n) 5
Fat-soluble vitamin supplements (n) 5
Proton-pump inhibitors or H1 receptor antagonists (n) 4
Ursodeoxycholate (n) 3
FEV1, forced expiratory volume in 1 s; SD, standard deviation; ICS, inhaled
corticosteroids.
All subjects were off of inhaled antibiotics at the time of FENO measurements.
a Results expressed as mean (SD or range) or frequency.
b Three subjects grew Pseudomonas aeruginosa, one grew Pseudomonas
fluorescens/putida.
c Prescribed inhaled antibiotic for chronic Pseudomonas aeruginosa infection
(tobramycin solution for inhalation or tobramycin inhalational powder).
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For this study, we examined whether acute changes in FENO
were a putative lower airway biomarker that could reflect restored
CFTR function in CF. To assess this, we performed pilot studies
to determine whether FENO measurements were repeatable over
short- and intermediate-term observations or influenced by acute
pulmonary disease status, and whether changes in FENO were
specific for CFTR modulator treatment and response. Our results
demonstrated that FENO measurements were quite stable in CF
patients over repeated measurements, and the clinical instabil-
ity associated with acute pulmonary exacerbations had little
effect on mean values or FENO variability. In contrast, FENO
did increase in response to ivacaftor across all patients (CohortTable 4
Changes in FENO, FEV1 percent predicted, weight, and sweat chloride over the 28
Visit FENO
(ppb)
FEV1
(% predicted)
Sweat C
(mM)
Pre-ivacaftor a 6.6
(2.2)
95.2
(12.1)
104.8
(9.9)
Post-ivacaftor a 11.8
(5.0)
105.4
(14.4)
46.8
(19.4)
Change b 5.2
(1.5, 8.9) c
10.2
(5.6, 14.8) c
−58.0
(−76.0,
Effect size d 1.4 0.8 −3.8
FENO, fractional excretion of exhaled nitric oxide; FEV1, forced expiratory volume
a Results expressed as mean (standard deviation).
b Results expressed as mean difference (95% conﬁdence interval).
c 95% conﬁdence interval for the mean difference does not include zero.
d Deﬁned as the ratio of the difference between pre- and post-ivacaftor treatmen
(decrease) in outcome over time.2), paralleling changes in FEV1 % predicted and reductions in
sweat chloride. These data support our hypothesis that in the
context of CF, acute increases in FENO reflect increases in
CFTR function rather than nonspecific improvements in lung
function status.
Variabilities of FENO during repeated testing was primarily
driven by intersubject factors, with 18.4% of the total
variability due to intrasubject contributions. Therefore, our
data suggest that FENO levels are reasonably stable within
individual CF patients over short and intermediate measure-
ment times, but relatively large differences can exist between
subjects. This is shown graphically in Fig. 1A, where FENO
levels ranged from 5 to 9 ppb across CF patients prior to
receiving treatment with ivacaftor and increased to 7–19 ppb
after ivacaftor treatment. The mean post-ivacaftor FENO values
for Cohort 2 were similar to the repeated FENO values
determined for Cohort 1 (11.8 ppb vs 10.7–10.9 ppb). Thus,
FENO values of CF subjects on ivacaftor therapy did not
segregate from the larger group of outpatient CF patients with
low predicted CFTR activity. In addition, the individual FENO
levels of the two G551D/F508del subjects on ivacaftor therapy
within Cohort 1 (8–13 ppb and 6–13 ppb) did not clearly differ
from the FENO values of the entire cohort (10.7–10.9 ppb).
The reasons for this intersubject variability are unclear, but
likely represent the numerous potential contributors to FENO
levels within each subject. Effect sizes in Cohort 2 showed
substantial separation between pre- and post-ivacaftor mea-
surements with respect to sweat chloride, FENO, and FEV1 %
predicted and modest separation based on change in BMI
percentile.
FENO recently has been demonstrated to have a moderate
inverse relationship with the lung clearance index or LCI and
moderate positive correlation with FEV1 % predicted in CF
patients with mild lung disease [16]. The difference between
CF subjects and healthy controls was primarily due to
bronchial-derived NO, but alveolar NO also was shown to
negatively correlate with peripheral inflammatory markers
(e.g., white blood count, platelets). Abnormal values of NO in
CF have recently been hypothesized to represent abnormal fatty
acid metabolism (increased arachidonic acid), infection, anddays of ivacaftor treatment.
l− Weight
(kg)
BMI
(kg/m2)
BMI
(percentile)
44.7
(16.4)
18.0
(3.0)
31.0
(19.1)
47.6
(17.1)
19.1
(3.4)
43.4
(27.1)
−40.0) c
2.9
(−1.4, 7.2)
1.0
(0.8, 2.8) c
12.4
(−11.1, 36.0)
0.2 0.3 0.5
in 1 s; Cl−, chloride; BMI, body mass index.
t means and pooled variance. A positive (negative) ratio implies an increase
A B
DC
Fig. 2. Individual changes in (A) FENO, (B) FEV1 % predicted, (C) sweat chloride, and (D) weight in CF patients with gating mutations, before and after one month
of ivacaftor therapy. Each curve is from an individual patient, with values to the left before ivacaftor and values to the right after one month of ivacaftor. Genotypes of
the five individual subjects were S549N/S549N (CF01-03), S549R/F508del (CF04), and G178R/F508del (CF05).
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has been shown to be reduced, and in these subjects with
moderate lung disease, no correlation of FENO with lung
function or microbiology was observed [29]. Zetterquist and
colleagues recently examined the role of oral bacteria in
NO measurements (exhaled breath condensate, saliva, and
FENO) by introducing an oral chlorhexidine wash to reduce
the contribution of oral flora [30]. This maneuver further
accentuated the difference between CF and controls and
highlights the many potential contributors to this measurement
in vivo. FENO has been reported to increase during treat-
ment of a pulmonary exacerbation in a small cohort (n = 14)
of hospitalized pediatric patients [17] with no correlation
with FEV1 % predicted improvement or microbiology
(P. aeruginosa infection). The reason for the discrepancy
between our findings in Cohort 1 and the study by Jaffe is
unclear, but may reflect the smaller numbers of subjects in the
original study, concomitant infections in our group, or diseaseseverity differences (baseline FEV1 of 72% in the current study
and 60% in [17]). Furthermore, our study was designed to
assess repeatability of FENO measurements during inpatient
therapy of pulmonary exacerbations, and these were not
specifically obtained at the initiation and completion of the
treatment period compared with the other study. Prolonged use
of rhDNAse also has been shown to increase FENO in a small
cohort of young CF patients with minimal lung disease (mean
FEV1 = 109% at baseline) compared with placebo [31]. In a
large cohort of CF patients (n = 75), FENO has been found to be
reduced in patients with specific NOS1 genetic polymorphisms
or P. aeruginosa or Aspergillus fumigatus infection and in the
presence of the F508del CFTR mutation [32]. Together these
studies indicate that FENO can have relationships to treatments
directed toward improving mucus clearance, reducing infection
and/or inflammation, infection status, CFTR genotype, and
NOS1 expression. The results of this study suggest that these
effects are minor relative to CFTR modulation.
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not completely understood, recent work by Mall and colleagues
in Cftr-knockout and beta ENaC-overexpressing mice indicates
that lung arginase expression is increased, particularly during
infection with P. aeruginosa [33], which would be predicted to
reduce the availability of local L-arginine for NO production
[34]. Pulmonary iNOS expression also has been reported to be
reduced in Cftr knockout mice [35], and together these studies
suggest reduced NO production as a contributor to low FENO
in CF patients in addition to those described above [17,34].
There were potential limitations of our study that should be
considered. As noted previously, our study was not designed to
test whether FENO levels rose during treatment of pulmonary
exacerbations and thus, it would be inaccurate to conclude that
exacerbation treatment does not influence FENO. Rather, we
found that repeated FENO measurements were stable during
clinical instability in the absence of initiation of CFTR
modulator treatment. Second, the range of lung function was
broad in our Cohort 1 study group and thus, disease subgroups
may demonstrate different FENO levels. An example of this
was seen in our subjects prescribed ICS (ICS treatment was at
the discretion of the treating physician, typically for significant
reversible airway obstruction), where weak correlations with
FENO were observed relative to patients not prescribed ICS. In
addition, as FENO is produced by diverse sources, the higher
levels in ICS-treated patients may relate to its impact on
inflammation and/or arginase activity. The increase in FENO
observed in Cohort 2 may also relate (in part) to the increase
in BMI seen during ivacaftor treatment. Weak positive
associations between FENO and BMI have been observed in
large cross-sectional studies, but these observations have been
inconsistent across studies (independent of CF diagnosis)
[36–38]. Finally, although we did measure adherence to therapies
outside of the hospitalized setting, the actual use of concomitant
medications during outpatient visits is unknown. Our observa-
tions in Cohort 2 of increases in FEV1 % predicted and decreases
in sweat chloride provide indirect evidence of ivacaftor
adherence and therefore, more confidence regarding the effect
of ivacaftor on FENO in this small group. What our study did
provide was a real-world assessment of FENO in a heavily treated
pediatric CF population using broad enrollment criteria that may
be of relevance to future clinical trial design and conduct.
In summary, FENO measurements in CF patients demon-
strated repeatability during inpatient and outpatient care (with
similar values across the four visits) with most of the variability
occurring between subjects. Correlations between FENO and
FEV1 % predicted were low and did not change over time, but
were weakly significant in patients with concomitant ICS use.
In subjects with gating mutations in CFTR that were treated
with ivacaftor, both FENO and FEV1 % predicted improved
over 28–30 days of treatment and sweat chloride was reduced.
Based on the stability of repeated measures during inpatient and
outpatient care in Cohort 1, we hypothesize that the acute
positive changes in FENO seen in Cohort 2 likely were specific
for restored CFTR function. This data indicates that further
investigation of FENO as a lower airway biomarker of CFTR
restoration is warranted.Funding
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